BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 17855486)

  • 21. Medical management update: multiple myeloma.
    Stoopler ET; Vogl DT; Stadtmauer EA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 May; 103(5):599-609. PubMed ID: 17291793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple myeloma: epidemiology and therapeutic options.
    Tuscano JM
    Manag Care; 2008 Jul; 17(7 Suppl 6):9-15. PubMed ID: 19093334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Multiple myeloma--recent advances in diagnosis and treatment].
    Chou T
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):304-8. PubMed ID: 15791813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Multiple myeloma--advances in disease biology and implications for therapy].
    Chou T
    Gan To Kagaku Ryoho; 2001 Sep; 28(9):1206-12. PubMed ID: 11579631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bortezomib in the front-line treatment of multiple myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New drugs in multiple myeloma.
    Berenson JR; Yellin O
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete remission of psoriasis after autologous hematopoietic stem-cell transplantation for multiple myeloma.
    Braiteh F; Hymes SR; Giralt SA; Jones R
    J Clin Oncol; 2008 Sep; 26(27):4511-3. PubMed ID: 18802165
    [No Abstract]   [Full Text] [Related]  

  • 28. Controversies regarding the use of dexamethasone in patients with multiple myeloma.
    Rajkumar SV
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):103, 141. PubMed ID: 18347560
    [No Abstract]   [Full Text] [Related]  

  • 29. Bortezomib plus melphalan and prednisone for multiple myeloma.
    Avvisati G
    N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090032
    [No Abstract]   [Full Text] [Related]  

  • 30. Drug insight: thalidomide as a treatment for multiple myeloma.
    Kumar S; Anderson KC
    Nat Clin Pract Oncol; 2005 May; 2(5):262-70. PubMed ID: 16264962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Recent progress in the treatment of multiple myeloma].
    Iida S
    Rinsho Ketsueki; 2007 Feb; 48(2):91-9. PubMed ID: 17370637
    [No Abstract]   [Full Text] [Related]  

  • 32. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
    Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K
    Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenalidomide: a new therapy for multiple myeloma.
    Palumbo A; Miguel JS; Sonneveld P; Moreau P; Drach J; Morgan G; Einsele H
    Cancer Treat Rev; 2008 May; 34(3):283-91. PubMed ID: 18230411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
    Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ;
    Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting multiple myeloma cells and their bone marrow microenvironment.
    Pagnucco G; Cardinale G; Gervasi F
    Ann N Y Acad Sci; 2004 Dec; 1028():390-9. PubMed ID: 15650264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel agents in myeloma: an exciting saga.
    Mark T; Niesvizky R; Coleman M
    Cancer; 2009 Jan; 115(2):236-42. PubMed ID: 19025986
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment for multiple myeloma: current status and future strategy in Japan].
    Iida S
    Rinsho Ketsueki; 2008 Oct; 49(10):1368-73. PubMed ID: 18833921
    [No Abstract]   [Full Text] [Related]  

  • 38. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
    Ciolli S; Leoni F; Casini C; Breschi C; Santini V; Bosi A
    Br J Haematol; 2008 Jun; 141(6):814-9. PubMed ID: 18410447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up.
    Popat R; Oakervee HE; Hallam S; Curry N; Odeh L; Foot N; Esseltine DL; Drake M; Morris C; Cavenagh JD
    Br J Haematol; 2008 May; 141(4):512-6. PubMed ID: 18371113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of multiple myeloma: the changing landscape.
    Reece DE
    Blood Rev; 2007 Nov; 21(6):301-14. PubMed ID: 17761373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.